Hepatitis C: A review of diagnosis, management, and ocular complications from treatment

Optometry

Volumn 74, Issue 8, 2003, Pages 517-523

  Tsolakos, Anna ^a   Zalatimo, Nadia ^b  

^a Nashua Eye Associates   (United States)

^b NONE

Author keywords

HCV; Hepatitis C virus; Interferon alpha; Interferon retinopathy; Peginterferon alpha

Indexed keywords

ALPHA2 INTERFERON; ALPHA2B INTERFERON; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CONSENSUS INTERFERON; ENZYME INHIBITOR; PEGINTERFERON ALPHA2B; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SERTRALINE; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR AGONIST; UNCLASSIFIED DRUG; ALPHA2A INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B; PEGINTERFERON ALPHA2A;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANOREXIA; BONE PAIN; CARDIOMYOPATHY; CASE REPORT; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONSULTATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DEPENDENCE; DRUG OVERDOSE; EYE DISEASE; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INJECTION SITE; INSOMNIA; INTERSTITIAL NEPHRITIS; INTRAOCULAR HEMORRHAGE; IRRITABILITY; ISCHEMIC OPTIC NEUROPATHY; LASER COAGULATION; MALE; MICROANEURYSM; MONITORING; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; OPTIC NERVE DISEASE; PAPILLEDEMA; PHARYNGITIS; PRURITUS; RELAPSE; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA FOVEA; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SIDE EFFECT; SINUSITIS; SUICIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN OCCLUSION; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; WEIGHT REDUCTION; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED; RETINA DISEASE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETINAL DISEASES; RIBAVIRIN;

EID: 0142087764     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(suppl 1):62S-65S.
3. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001;85:1171-3.
4. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-6.
5. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
6. Koff RS. Hepatitis C. In: Gorbach S, Bartlett J, Blacklow N, eds. Infectious diseases, 2nd ed. Philadelphia: Saunders Company, 1998: 864-9.
7. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
8. Saunders CS. Update on hepatitis C infection. Patient Care 2001:1-14.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
10. Bren L. Hepatitis C: an update. FDA Consum 2001; 35(1):12-3.
11. Baron S, Tyring SK, Fleischmann WR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991;266:1375-83.
12. U.S. Food and Drug Administration FDA Talk Paper. August 8, 2001. U.S. Food and Drug Administration. April 2, 2002 http://www.fda.gov/bba/topics/ ANSWERS/ ANS01096.html
13. Product information sheet. Kenilworth, N.J.: Schering Corporation, 2000.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
15. United States Department of Veterans Affairs National Hepatitis C Program Home Page. 19 August 19, 2002. U.S. Department of Veterans Affairs. Septempter 9, 2002 http:// www..va.gov/hepatitisc/
16. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
17. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
18. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
19. Ikebe T, Nakatsuka K, Goto M, et al. A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn 1990;41:2291-6.
20. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-13.
21. Esmaeli B, Koller C, Papadopoulos N, et al. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001;108:858-60.
22. Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999;13:241-6.
23. Hejny C, Sternberg P Jr, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001;131:782-7.
24. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113: 1041-4.
25. Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon associated retinopathy. Br J Ophthalmol 1998;82:323-5.
26. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjuctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79:150-2.
27. Nishiwaki H, Ogura Y, Miyamoto K, et al. Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996;114:726-30.
28. Nishiwaki H, Yuichiro O, Miyamoto K, et al. Prednisolone, platelet-activating factor receptor agonist, or superoxide dismutase reduced leukocyte entrapment induced by interferon alpha in retinal microcirculation. Invest Ophthalmol Vis Sci 1997;38:811-6.
29. Willson RL, Ross RD, Willson LM, et al. Interferon-associated retinopathy in a young, insulin-dependent diabetic patient. Retina 2000;20:413-5.